Aurobindo Pharma gets U.S. FTC go-ahead to acquire Lannett Company
Aurobindo Pharma has received FTC approval to acquire Lannett Company for $250 million. The deal aims to bolster Aurobindo's U.S. manufacturing capabilities and expand its portfolio of non-opioid controlled substances.
Why it matters
This acquisition strengthens domestic pharmaceutical supply chains in the U.S. and consolidates the generic drug market.
The U.S. Federal Trade Commission (FTC) has approved Aurobindo Pharma’s proposed acquisition of Pennsylvania-based generic pharmaceutical firm Lannett Company.
The article reports on a corporate acquisition using neutral, factual language based on official company and regulatory statements.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in